(24/7 MARKET NEWS) – Cidara Therapeutics, Inc. (Nasdaq: CDTX) and Melinta Therapeutics, LLC reported, this morning, that the FDA Antimicrobial Drugs Advisory Committee voted favorably 14 to 1 that Cidara, as part of its New Drug Application (NDA), provided sufficient evidence supporting a favorable benefit-risk assessment for a limited use indication for rezafungin for the treatment of candidemia and invasive candidiasis in adult patients with limited or no alternative treatment options.
Cidara Therapeutics opened this morning’s trading at $1.07 and is now at $0.9616, up $0.0335 (+3.61%), on volume of 10 million shares traded.
Its 52-week range is $0.40 to $1.60. Its next key inflection points are $1.41, $1.53, and this morning’s premarket high of $1.68. If can break through the $1.68 resistance level, on strong volume, it could try to challenge its February trading levels.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
